Approach to High-Risk Multiple Myeloma

Xiaoyi Chen; Gaurav Varma; Faith Davies; Gareth Morgan

doi:10.1016/j.hoc.2023.12.008

Approach to High-Risk Multiple Myeloma

Hematol Oncol Clin North Am. 2024 Apr;38(2):497-510. doi: 10.1016/j.hoc.2023.12.008. Epub 2024 Jan 8.

Authors

Xiaoyi Chen¹, Gaurav Varma¹, Faith Davies¹, Gareth Morgan²

Affiliations

¹ Center Blood Cancer, Perlmutter Cancer Center, New York University, NYCLangone, Room# 496, Medical Science Building 4th Floor, 540 1st Avenue, New York, NY 10016, USA.
² Center Blood Cancer, Perlmutter Cancer Center, New York University, NYCLangone, Room# 496, Medical Science Building 4th Floor, 540 1st Avenue, New York, NY 10016, USA. Electronic address: Gareth.morgan@NYULangone.org.

PMID: 38195306
DOI: 10.1016/j.hoc.2023.12.008

Abstract

Improving the outcome of high-risk myeloma (HRMM) is a key therapeutic aim for the next decade. To achieve this aim, it is necessary to understand in detail the genetic drivers underlying this clinical behavior and to target its biology therapeutically. Advances have already been made, with a focus on consensus guidance and the application of novel immunotherapeutic approaches. Cases of HRMM are likely to have impaired prognosis even with novel strategies. However, if disease eradication and minimal disease states are achieved, then cure may be possible.

Keywords: Aggressive; Biology; Genetics; Guidance; High-risk; Myeloma; Treatment.

Publication types

Review

MeSH terms

Humans
Multiple Myeloma* / diagnosis
Multiple Myeloma* / genetics
Multiple Myeloma* / therapy
Prognosis